Navigating the research peptide landscape requires identifying an ARA-290 vendor capable of delivering rigorously tested, high-purity compounds backed by transparent analytical data. As an erythropoietin-derived peptide tailored for innate repair receptor (IRR) investigation, ARA-290 demands strict analytical validation including HPLC purity and mass spectrometry confirmation prior to laboratory deployment.
Navigating the research peptide landscape requires identifying an ARA-290 vendor capable of delivering rigorously tested, high-purity compounds backed by transparent analytical data. As an erythropoietin-derived peptide tailored for innate repair receptor (IRR) investigation, ARA-290 demands strict analytical validation including HPLC purity and mass spectrometry confirmation prior to laboratory deployment.
A qualified ARA-290 vendor must provide lot-specific third-party Certificate of Analysis (COA) documentation demonstrating purity equal to or exceeding 98% via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and mass spectrometry (ESI-MS). For valid in vitro and animal models, the vendor must guarantee USA-based synthesis under ISO 17025 accredited testing conditions with confirmed low endotoxin levels.
When purchasing compounds for cellular or preclinical assays, research institutions must prioritize supply chain integrity over unverified digital distributors. PX1 Research manufactures research peptides under strict analytical oversight, fulfilling the stringent chemical verification requirements demanded by academic, industrial, and biotechnology laboratories.
ARA-290 (also known in scientific literature as Cibinetide or pyroglutamate helix B surface peptide) is a synthetic 11-amino acid peptide derived from the tertiary structure of erythropoietin (EPO). Unlike native EPO, which interacts primarily with homodimeric erythropoietin receptors (EPOR2) to stimulate erythropoiesis, ARA-290 was designed to selectively bind the heterodimeric Innate Repair Receptor (IRR).
The molecular structure of ARA-290 isolates the tissue-protective helix B domain of EPO. This structural refinement eliminates hematopoietic activity—meaning it does not stimulate red blood cell production—while preserving the signal transduction cascades involved in cellular protection, anti-inflammatory signaling, and tissue remodeling. For investigators navigating our research library hub, understanding this molecular selectivity is key when designing targeted preclinical assays.
Because of its specific sequence (pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH), maintaining structural stability during synthesis is paramount. Substandard manufacturing by an unverified ARA-290 vendor can lead to truncated sequences or racemized side chains, which compromise binding affinity at the receptor interface.
The primary mechanism of ARA-290 revolves around its specific high-affinity interaction with the Innate Repair Receptor (IRR). The IRR is a heterotrimer composed of one erythropoietin receptor (EPOR) subunit and one beta-common receptor (CD131) subunit. Under physiological homeostasis, expression of the IRR is low; however, upon exposure to metabolic stress, pro-inflammatory cytokines, or mechanical tissue injury, cellular expression of CD131 upregulated rapidly across endothelial, neuronal, and parenchymal cells.
Preclinical studies suggest that when ARA-290 engages the IRR, it triggers intracellular phosphorylation cascades that inhibit nuclear factor kappa B (NF-κB) nuclear translocation. NF-κB serves as a master transcriptional regulator for inflammatory mediators, including TNF-alpha, IL-1beta, and IL-6. By blunting NF-κB activation, ARA-290 downstream signaling attenuates pro-inflammatory cytokine cascades and limits apoptosis in stressed tissue models.
Additionally, in vitro assays demonstrate that IRR activation via ARA-290 recruits the Akt and ERK1/2 signaling pathways. These pathways promote cell survival, microvascular integrity, and localized tissue remodeling. Researchers analyzing downstream signal transduction frequently consult our detailed breakdown of ARA-290 mechanism of action for experimental assay design.
In animal models of metabolic disturbance, inflammatory stress, and nerve injury, ARA-290 has emerged as a critical tool for examining tissue-protective signaling. Literature indicates that in rodent models of peripheral neuropathy, ARA-290 administration correlates with reduced mechanical allodynia, decreased intraepidermal nerve fiber degeneration, and suppressed microglial activation within the spinal dorsal horn.
In vitro data indicate that ARA-290 protects vascular endothelial cells from ischemia-reperfusion injury and oxidative stress. By stabilizing endothelial tight junctions and preventing hyperpermeability, the peptide helps maintain tissue perfusion and mitigates cellular edema in preclinical organ preservation models.
Furthermore, research evaluating metabolic dysfunction demonstrates that IRR agonism by ARA-290 modulates macrophage polarization, shifting cellular phenotypes from pro-inflammatory M1 states to reparative M2 states. Investigators exploring broader tissue repair pathways can review our comprehensive directory of peptides for tissue repair research to compare mechanisms across structural classes.
Because synthetic peptides are prone to chemical degradation, incomplete coupling, and residual solvent contamination during solid-phase peptide synthesis (SPPS), selecting a qualified ARA-290 vendor requires thorough verification of analytical documentation. Laboratories should never rely on generic certificates of analysis or batch guarantees that lack raw analytical data.
A compliant vendor must provide a lot-specific Certificate of Analysis featuring two core analytical tests:
1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): This assay measures chemical purity by separating the target peptide from synthesis artifacts, truncated sequences, and deletion peptides. A reputable supplier ensures a purity threshold of ≥98% area under the curve.
2. Electrospray Ionization Mass Spectrometry (ESI-MS): While HPLC confirms purity, mass spectrometry verifies molecular identity. The observed mass-to-charge (m/z) ratio must match the theoretical molecular weight of ARA-290 (1257.34 Da) precisely, ruling out sequence errors or incorrect amino acid substitution.
At PX1 Research, every production lot undergoes independent verification at an ISO 17025 accredited laboratory, ensuring full analytical transparency for academic and industrial research environments.
In cell culture and animal model research, bacterial endotoxins (lipopolysaccharides or LPS) represent a major confounding variable. Presence of trace endotoxins in a research compound can trigger immune responses through Toll-Like Receptor 4 (TLR4) activation, completely skewing experimental data related to inflammatory signaling, NF-κB pathways, and cytokine release.
When evaluating an ARA-290 vendor, verify that the supplier conducts Limulus Amebocyte Lysate (LAL) or recombinant Factor C testing on every lot. Research-grade compounds intended for sensitive in vitro assays or in vivo administration models should demonstrate endotoxin levels under strict thresholds, ideally <0.01 EU/mg.
PX1 Research enforces strict sterility and endotoxin limits, manufacturing compounds in USA-based, GMP-compliant facilities. This guarantees that observed biological effects stem solely from the peptide target rather than bacterial contaminants.
To properly contextualize ARA-290 within a research framework, investigators often evaluate its performance alongside other signal-modulating and cytoprotective compounds. While ARA-290 acts specifically via the heterodimeric Innate Repair Receptor, other synthetic peptides target alternative pathways involved in cellular repair and inflammatory resolution.
For instance, BPC-157 is widely studied in preclinical models for its focal adhesion kinase (FAK) and VEGFR2-mediated angiogenic pathways, whereas KPV functions as a tripeptide derivative of alpha-MSH, exerting anti-inflammatory effects through direct nuclear translocation inhibition without EPO-receptor involvement. Similarly, TB-500 operates via actin-sequestering mechanisms through its G-actin binding domain. Comparing these distinct pathways helps researchers select the exact molecular tool required for their specific cell-signaling assays.
For labs seeking diverse molecular probes across multiple pathways, explore our full catalog of research compounds at all peptides.
Proper handling and storage protocols are essential to preserve the structural integrity of ARA-290 upon receipt from your vendor. The lyophilized peptide is stable at room temperature for short transport periods but should be stored long-term at -20°C or -80°C in a desiccated environment away from light.
When preparing ARA-290 for laboratory assays, adhere to standard reconstitution protocols:
1. Equilibration: Allow the vial to reach room temperature before opening to prevent moisture condensation within the container.
2. Solvent Selection: Reconstitute using sterile Bacteriostatic Water, Sterile Water for Injection (SWFI), or phosphate-buffered saline (PBS, pH 7.4) depending on the sensitivity of your downstream assay.
3. Dissolution: Add the solvent along the inner glass wall of the vial. Gently swirl or invert the container. Avoid vigorous vortexing, which can introduce shear forces that induce peptide denaturation or aggregation.
4. Aliquoting: Once reconstituted, aliquot the solution into single-use microcentrifuge tubes to eliminate freeze-thaw cycles, which degrade peptide stability. Store liquid aliquots at -20°C or below for extended assay timelines.
High-throughput screening, multi-arm animal trials, and long-term longitudinal studies require consistent batch-to-batch reproducibility and stable supply chains. Variations between vendor batches can introduce confounding variables that compromise experimental reproducibility across trial phases.
PX1 Research provides institutional supply options tailored to university laboratories, contract research organizations (CROs), and private research facilities. Through our dedicated wholesale lab account portal, institutional buyers can secure high-quantity lots with guaranteed lot reservation, full analytical COAs, and direct access to US-based technical support.
Orders placed Monday through Friday ship same-day from our facility locations in California and Arizona, ensuring minimal transit time and temperature stability for your critical laboratory reagents.
What is the purity level of PX1 Research ARA-290?
PX1 Research guarantees an analytical purity level of ≥98% for ARA-290, verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and mass spectrometry (ESI-MS).
How is ARA-290 tested for endotoxins?
Every lot of ARA-290 undergoes rigorous Limulus Amebocyte Lysate (LAL) or recombinant Factor C testing to ensure endotoxin levels remain below strictly controlled research thresholds (<0.01 EU/mg).
Where are PX1 Research peptides manufactured and shipped from?
PX1 Research peptides are synthesized in USA-based, GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona with same-day dispatch for orders placed M–F.
Can ARA-290 be used in human clinical trials or personal administration?
No. ARA-290 sold by PX1 Research is strictly designated for laboratory research use only (in vitro and preclinical animal models). It is not for human, clinical, therapeutic, or diagnostic application.
What analytical documents are included with an ARA-290 shipment?
Each shipment includes access to a lot-specific Certificate of Analysis (COA) containing raw RP-HPLC chromatograms, mass spectrometry spectra, and endotoxin verification data.
What solvent should be used to reconstitute ARA-290 for in vitro assays?
Depending on assay design, ARA-290 can be reconstituted in sterile Bacteriostatic Water, Sterile Water for Injection, or sterile phosphate-buffered saline (PBS, pH 7.4).
How does ARA-290 differ structurally from native erythropoietin (EPO)?
ARA-290 is an 11-amino acid peptide derived specifically from the helix B surface of EPO. It selectively binds the heterodimeric Innate Repair Receptor (IRR) without binding the homodimeric EPO receptor, making it non-hematopoietic.
Does PX1 Research offer bulk pricing for institutional laboratories?
Yes. Qualified academic, industrial, and institutional research facilities can request bulk quantities and batch reservations through our wholesale program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.